ISRCTN85819697已完成未知
Immunogenicity and reactogenicity of concomitantly administered hexavalent and Group B meningococcal vaccines in infancy
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 194
研究概览
简要总结
2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36476534/ (added 05/01/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •For recruitment to all study groups, participants MUST FULFILL each of the below criterion:
- •1. Parents/legal guardians are over 16 years of age, and are willing and able to consent to enrol their child/children in the study
- •2. Parents/legal guardians able to comply with the requirements of the trial protocol and have internet access for the duration of the study
- •3. Parents/legal guardians are willing to allow their General Practitioner, health visitor and consultant, if appropriate, to be notified of participation in the trial
- •4. Participants born at greater than or equal to 37 weeks gestation
- •5. Participants are due to receive their primary immunisations, aged 8 to 13 weeks (i.e. the day the child turns 13 weeks of age) at enrolment
排除标准
- •The participant may not enter the trial IF ANY of the following apply:
- •1. Parents/legal guardians of children are on the delegation log of this study
- •2. Confirmed or suspected immunodeficiency
- •3. Fulfil any of the contraindications to vaccination as specified in The Green Book
- •4. Confirmed anaphylactic reaction/s to any constituent/s or excipient/s of the vaccine(s)
- •5. Confirmed anaphylactic reaction to neomycin, streptomycin or polymyxin B (which may be present in trace amounts in the tetanus vaccine), kanamycin, histidine, sodium chloride or sucrose (which may be present in trace amounts in the Meningococcal B vaccine) or to gelatin (which may be present in trace amounts in the MMR vaccine)
- •6. Latex hypersensitivity (the syringe cap of the Meningococcal B vaccine, Bexsero may contain natural rubber latex)
- •7. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial
- •8. Thrombocytopenia or any other bleeding disorders.
- •9. Child is currently participating in another interventional clinical trial
- •Temporary exclusions for all groups
- •For a vaccination visit only (visit 1, 2, 3, and 5)
- •1. Administration of any other vaccine within 14 days prior to study vaccines
- •2. Scheduled elective surgery, planned admission or other procedures requiring general anaesthesia within 7 days of receiving a vaccine
- •3. Febrile illness (axillary temperature > = 38.0°C) within the previous 24 hours or on the day of vaccination
- •For a blood sampling visit only (visit 4 and 6)
- •Have received parenteral or oral antibiotics within the last 7 days
研究者
相似试验
已完成
不适用
Safety and immunogenicity of concomitant administration of a virosomal hepatitis A vaccine (Epaxal®) with DTP, aHib, IPV, OPV and MMR vaccines versus non-concomitant administration in 12 to 15 month-old childreHepatitis AISRCTN82277382Berna Biotech Ltd (Switzerland)322
已完成
不适用
Mixing of the COVID-19 vaccines Covishield and Covaxin for safety assessmentCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN98052401Asian Healthcare Foundation44
已完成
1 期
Immune response to Shingrix vaccination in patients with chronic lymphocytic leukemia or Waldenstrom macroglobulinemia while undergoing treatment with BTK inhibitorsChronic lymphocytic leukemia or Waldenstrom macroglobulinemiaCancerISRCTN78423540niversity of Rochester32
已完成
2 期
Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's LymphomaLymphomaNCT00307710M.D. Anderson Cancer Center28
已完成
3 期
Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult SubjectsProphylaxis: InfluenzaNCT02256488Novartis Vaccines1,561